Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Reviews

Recent research trends and updates on nonalcoholic fatty liver disease

Jeong-Ju Yoo, Won Kim, Moon Young Kim, Dae Won Jun, Sang Gyune Kim, Jong-Eun Yeon, Jin Woo Lee, Yong Kyun Cho, Sang Hoon Park, Joo Hyun Sohn

Clin Mol Hepatol. 2019;25(1):1-11. Published online August 8, 2018

Web of Science 70 Crossref 66

DOI: https://doi.org/10.3350/cmh.2018.0037

Pathologic differential diagnosis of metastatic carcinoma in the liver

Jeong Hwan Park, Jung Ho Kim

Clin Mol Hepatol. 2019;25(1):12-20. Published online October 5, 2018

Web of Science 40 Crossref 45

DOI: https://doi.org/10.3350/cmh.2018.0067

Radiomics and radiogenomics of primary liver cancers

Woo Kyoung Jeong, Neema Jamshidi, Ely Richard Felker, Steven Satish Raman, David Shinkuo Lu

Clin Mol Hepatol. 2019;25(1):21-29. Published online November 16, 2018

Web of Science 46 Crossref 49

DOI: https://doi.org/10.3350/cmh.2018.1007

Discussion on critical points for a tailored therapy to cure hepatitis C virus infection

Nadia Marascio, Angela Quirino, Giorgio Settimo Barreca, Luisa Galati, Chiara Costa, Vincenzo Pisani, Maria Mazzitelli, Giovanni Matera, Maria Carla Liberto, Alfredo Focà, Carlo Torti

Clin Mol Hepatol. 2019;25(1):30-36. Published online January 23, 2019

Web of Science 14 Crossref 17

DOI: https://doi.org/10.3350/cmh.2018.0061

Editorials

Biomarker microfibril-associated glycoprotein 4 for non-invasive diagnosis and therapeutic evaluation of hepatic fibrosis in patients with hepatitis C

Young Woo Eom, Soon Koo Baik

Clin Mol Hepatol. 2019;25(1):37-39. Published online December 11, 2018

Web of Science 2 Crossref 2

DOI: https://doi.org/10.3350/cmh.2018.1011

Can hepatic steatosis really promote hepatitis B viral hepatocarcinogenesis? The jury is out on.

Won Kim

Clin Mol Hepatol. 2019;25(1):40-41. Published online December 28, 2018

Web of Science 1 Crossref 1

DOI: https://doi.org/10.3350/cmh.2018.0101

Original Articles

Direct-acting antivirals-based therapy decreases hepatic fibrosis serum biomarker microfibrillar-associated protein 4 in hepatitis C patients

Christian Mölleken, Maike Ahrens, Anders Schlosser, Julia Dietz, Martin Eisenacher, Helmut E. Meyer, Wolff Schmiegel, Uffe Holmskov, Christoph Sarrazin, Grith Lykke Sorensen, Barbara Sitek, Thilo Bracht

Clin Mol Hepatol. 2019;25(1):42-51. Published online November 19, 2018

Web of Science 13 Crossref 14

DOI: https://doi.org/10.3350/cmh.2018.0029

Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic hepatitis B

Yun Bin Lee, Yeonjung Ha, Young Eun Chon, Mi Na Kim, Joo Ho Lee, Hana Park, Kwang-il Kim, Soo-Hwan Kim, Kyu Sung Rim, Seong Gyu Hwang

Clin Mol Hepatol. 2019;25(1):52-64. Published online October 23, 2018

Web of Science 78 Crossref 77

DOI: https://doi.org/10.3350/cmh.2018.0040

Efficacy of L-carnitine on ribavirin-induced hemolytic anemia in patients with hepatitis C virus infection

Shinya Sato, Kei Moriya, Masanori Furukawa, Soichiro Saikawa, Tadashi Namisaki, Mitsuteru Kitade, Hideto Kawaratani, Kosuke Kaji, Hiroaki Takaya, Naotaka Shimozato, Yasuhiko Sawada, Kenichiro Seki, Koh Kitagawa, Takemi Akahane, Akira Mitoro, Yasushi Okura, Junichi Yamao, Hitoshi Yoshiji

Clin Mol Hepatol. 2019;25(1):65-73. Published online February 25, 2019

Web of Science 5 Crossref 4

DOI: https://doi.org/10.3350/cmh.2018.0070

Safety margin of embolized area can reduce local recurrence of hepatocellular carcinoma after superselective transarterial chemoembolization

Kittipitch Bannangkoon, Keerati Hongsakul, Teeravut Tubtawee, Teerha Piratvisuth

Clin Mol Hepatol. 2019;25(1):74-85. Published online February 28, 2019

Web of Science 21 Crossref 23

DOI: https://doi.org/10.3350/cmh.2018.0072

Letter to the Editor

Biochemical profile in an infant with neonatal hemochromatosis shows evidence of impairment of mitochondrial long-chain fatty acid oxidation

Karina Lucio de Medeiros Bastos, Caio Robledo Quaio, Fabiana Roberto Lima, Iana Manuelle Araújo, Candice Alves Tavares Araújo, Flávia Balbo Piazzon, Ismael Dale Cotrim Guerreiro da Silva, Gabriel Nuncio Benevides, Ana Cristina Tannuri, Uenis Tannuri, Ramiro Anthero Azevedo, Chong Ae Kim

Clin Mol Hepatol. 2019;25(1):86-91. Published online August 28, 2018

Web of Science 2 Crossref 1

DOI: https://doi.org/10.3350/cmh.2018.0005

Viewed By 4951	MAFLD: How is it different from NAFLD?
Viewed By 4831	Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations
Viewed By 4740	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4455	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Viewed By 4413	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 214	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 155	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 133	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 117	MAFLD: How is it different from NAFLD?
Cited By 95	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Previous issues